WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 22, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise ImmunoGen to Receive $40 Million Upfront Payment and is Eligible to
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 12, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of approximately $54.8 million through its At-the-Market (“ATM")
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 5, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2020 the compensation committee of the Company’s Board of Directors granted a
Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 17, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 2, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on August 31, 2020 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 3, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified
Encouraging Data from FORWARD II Study of Mirvetuximab in Combination with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Preclinical Data on Next Generation Anti-FRα ADC, IMGN151, Demonstrating Enhanced Anti-Tumor Activity, Presented at AACR Positive